Möchten Sie immer auf dem neuesten Stand bleiben?

Trial initiation in food allergy follows promising results in Phase 2 trial in chronic spontaneous urticaria, another IgE-driven conditionRAPT seeks to develop a differentiated anti-IgE therapy for...

SAN CARLOS, Calif., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea,” “Biomea Fusion” or the “Company”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity medicines company, today...

Brekiya® autoinjector, a new specialty therapy from Amneal, is now available for prescription exclusively through Walgreens Specialty Pharmacy and Sterling Specialty Pharmacy BRIDGEWATER, N.J., Oct. ...

– All myositis patients in the Phase 1/2 DM/ASyS cohort with sufficient follow-up who met key registrational inclusion criteria exceeded the registrational primary endpoint, demonstrating major TIS...

interface.ai Expands Leadership Team with Steve Swanston as CRO to Advance its Mission of Transforming Banking Through Agentic AI

KT-579, a potent, selective, oral degrader of IRF5, demonstrated broad activity across multiple preclinical models of lupus and rheumatoid arthritis (RA), with activity comparable or superior to...

Tonmya demonstrated significant reduction in fibromyalgia pain compared with placebo in the Phase 3 RESILIENT studyTreatment was well tolerated with minimal effects on weight or blood pressure and...

The publication reports the highly selective, DCAF16 E3 enabled degradation of BRD9 in vivo using Amphista’s proprietary, next generation Targeted Glue™ medicinal chemistry technologyAmphista’s...

TAIPEI, Taiwan, Oct. 27, 2025 (GLOBE NEWSWIRE) -- LionFans, a Taiwan-based leader in social media marketing technology, today announced a major upgrade to its proprietary SmartSync™ system,...

HARBIN, China, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Recently, the second "Global Harmony - Heilongjiang in Songs" International cultural exchange performance was successfully held at the Concert Hall...